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Background: The purpose of this study was to identify a real-world US population having 
undergone surgery for malignant melanoma and describe treatment patterns, health care resource 
utilization, and costs for patients who subsequently received interferon alfa-2b (IFN) therapy 
or other standard of care chemotherapies.
Methods: A retrospective cohort study was conducted using administrative claims from 
MarketScan® databases among melanoma patients diagnosed between 2004 and 2008 who had 
surgery and were subsequently treated with IFN or other chemotherapies. Health care resource 
utilization and costs of services (converted to 2009 dollars) were evaluated. Cost refers to the 
amount paid to providers associated with the health service.
Results: Of 18,075 subjects with melanoma surgery claims, 1525 (8.4%) were treated with 
IFN and 1194 (6.6%) with other chemotherapies. Median duration (days) and number of doses 
of IFN therapy were 29 and 20, respectively. Approximately half of patients who received IFN 
discontinued therapy within or after the one-month induction phase. For IFN therapy patients, 
average total cost per patient for the last melanoma-related surgery prior to start of therapy, 
including costs of the surgery itself, pathology, anesthesia, and hospital care, was $2219. The 
average total cost per patient related to IFN therapy was $1188; this included costs for drug, office 
visits, blood work, and infusions. Other chemotherapy costs ranged from $146 to $2678.
Conclusion: There is an unmet treatment need, considering that this study observed that mela-
noma patients on IFN therapy post-surgery do not complete the recommended one-year course 
of treatment which may compromise its full therapeutic benefits. Further study to investigate 
reasons for discontinuation may be warranted. In addition, costs associated with adjuvant IFN 
therapy in post-surgical treatment of disease are likely acceptable.
Keywords: malignant melanoma, interferon alfa-2b, post-surgery, claims data, costs, resource 
utilization
Introduction
In the US in 2010, malignant melanoma was the fifth and seventh most common cancer 
diagnosed in men and women, respectively,1 and the number of new cases (excluding 
basal cell and squamous cell carcinoma) was estimated at 68,130.2 Among the available 
treatment options for malignant melanoma, surgical resection with or without lymph node 
sampling represents the standard of care and allows for staging, regional control of the 
disease, and, possibly, improved survival. In the US, patients with stage III   melanoma 
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undergo resection of primary tumors and all involved nodal 
basins with the aim of reducing the likelihood of tumor 
recurrence.3–5 Approximately 85%–90% of Stage III patients 
undergo surgery (lymphadenectomy or excision surgery). 
According to national guidelines, adjuvant therapy is offered 
to patients with stage III disease who have undergone surgery 
as the primary treatment and consists primarily of treatment 
with interferon alfa, but may also include observation, other 
treatments, or enrollment into clinical trials.6
Interferon alfa-2b (Intron® A or IFN) is an immu-
notherapy indicated as adjuvant to surgical treatment in 
patients 18 years of age or older with malignant melanoma 
who are free of disease but at high risk of systemic recur-
rence within 56 days of surgery.7 High-dose IFN over the 
long term has been shown to increase relapse-free survival.8 
It is approved as adjuvant therapy for high-risk (stages IIB, 
IIC, and III) melanoma.7 On the other hand, chemotherapy 
is usually reserved for late-stage patients with metastatic 
disease (stage IV).
There are currently no published studies in the US on the 
real-world proportion of melanoma patients who receive IFN 
therapy following surgery and there are limited data on treat-
ment patterns and costs specifically associated with adjuvant 
IFN treatment in melanoma patients following surgery.9–11 
Using administrative claims data, the aims of this study 
were to: identify a real-world population which had under-
gone surgery for malignant melanoma and the proportion of 
those patients who had received IFN therapy post-surgery; 
describe the duration and frequency of IFN therapy; and 
describe the health care resource utilization (HCRU) and 
costs associated with the last surgery prior to start of IFN 
therapy, IFN therapy, and other selected chemotherapy agents 
used to treat melanoma post-surgery.
Materials and methods
Design and setting
The study was a retrospective cohort analysis of two Thomson 
Reuters MarketScan® Research databases.12 The Thomson 
Reuters MarketScan Commercial Claims and Encounters data-
base contains details of annual inpatient, outpatient, emergency 
room, and outpatient prescription drug claims of several 
  million individuals covered under a variety of fee-for-service 
and capitated health plans. The Thomson Reuters MarketScan 
Medicare Supplemental and Coordination of Benefits database 
includes both the Medicare-paid portion and the employer-paid 
supplemental portion of payment. Neither database includes 
death data. Data were extracted in April 2011.
Subjects and treatments
Five cohorts were formed and are described with their 
  inclusion criteria as follows:
•	 Cohort A included patients over the age of 18 years with 
a confirmed melanoma diagnosis claim based on ICD9 
diagnosis codes (172.0–172.9 and V10.82) between 
  January 1, 2004 and December 31, 2008 in either the 
primary or secondary position of an insurance claim in 
any health care setting. The index melanoma diagnosis 
event was defined as the first medical event for melanoma 
based on the diagnosis code for a given patient occurring 
during the time window.
•	 Cohort B consisted of patients from cohort A with 
  confirmed claim(s) for a surgical intervention procedure 
related to melanoma. The index surgery event was defined 
as the first medical claim for a surgical intervention 
related to melanoma based on CPT4 reimbursement codes 
and ICD9 code 403. Cohort B was further examined to 
determine those patients whose surgery was performed 
following melanoma diagnosis (based on their index 
surgery date being after their index melanoma diagnosis 
date), and those who were diagnosed after surgery (based 
on their index surgery date being prior to a melanoma 
diagnosis).
•	 Cohort C1 included patients from cohort B with   confirmed 
claim(s) for IFN therapy within 60 days of a post-surgery 
claim. Patients needed to have started therapy prior to 
January 1, 2009.
•	 Cohort C2 included the remaining patients from cohort 
B who did not have a claim for IFN therapy, and 
therefore consists of patients who received any other 
non-IFN   therapy within 60 days post-surgery claim. 
Non-IFN therapy includes any medications taken by the 
patient, including those used to treat melanoma, such as 
chemotherapies but not IFN, or those to treat any other 
concomitant disease (not classified).
•	 Cohort C3 consists of patients from cohort C2 who 
received chemotherapeutic drugs considered standard of 
care for regional and distant metastatic melanoma based 
on National Comprehensive Cancer Network guidelines,6 
specifically carboplatin, cisplatin, dacarbazine, paclitaxel, 
or temozolomide.
No continuous enrollment criteria were applied for the 
study. For cost data, only those related to a fee-for-service 
plan type were collected (average enrollee distribution from 
2004 to 2008 was 81% for fee-for-service and 19% for the 
capitated health plan type).
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Data analyses
The duration of IFN therapy 60 days post-surgery was ana-
lyzed separately by induction phase (defined as 0–29 days 
from start of IFN therapy) and maintenance phase (.29 days 
from start of IFN therapy). A window of 29 days was 
used from the start date of IFN therapy because   induction 
therapy for Intron A consists of 4 weeks (28 days).7 
  Thereafter, any claim was considered maintenance. Patients 
were censored at 12 months of IFN therapy.
The frequency of doses of IFN therapy among   melanoma 
patients who received IFN therapy within 60 days post-surgery 
was estimated based on the number of claims recorded in the 
database. During the induction phase, it was assumed that 
patients also had claims related to office visits (for infusion 
administration).
For melanoma-related surgery, costs were collected 
for the last surgery claim prior to the start of drug therapy 
and using a ± one-day window. Services considered under 
melanoma-related surgery included the surgery itself, 
plus associated anesthesia, pathology, and hospital care 
captured from cohort C1. Surgery claims included those 
related to lymph node biopsy, removal or excision, and 
  lymphadenectomy. Pathology claims included those related 
to any consultations, pathologist examinations, or procedures 
that occurred. Claims for observation, same day admissions, 
inpatient care, and associated consultations were considered 
hospital care.
Drug acquisition costs were based on costs related to the 
drug reimbursement (J) code for each product, including oral 
formulations where available. Claims associated with use 
of IFN according to the label were captured, reflecting tests 
normally required for monitoring with IFN use; any other 
routine laboratory tests that patients had done during their 
treatment period (that were not related to their melanoma 
treatment) were not considered.7 Services related to the use of 
IFN therapy included complete blood count panels, thyroid-
releasing hormone stimulation tests, infusion administrations, 
and associated office visits.
Cost refers to the amount paid to providers associated 
with the claim or health service including copayment(s) 
and/or coinsurance. All service costs are represented as 2009 
costs. Costs were adjusted for yearly inflation based on the 
consumer price index medical care expenditure category, 
using 2009 as the base case.13
The average unit cost per service per patient, across all 
claim codes (ICD9, CPT4, J) for that service, was calculated 
by averaging across all patients the cumulative sum of the 
costs incurred for a specific service by the total number of 
claims for the given service within each patient. A listing of 
all codes included in the analysis is available in Supplemen-
tary Table S1.
Results
Characteristics of patient population
Of the 178,817 melanoma patients identified in the   Market 
Scan databases (Figure 1), 18,075 had a confirmed claim for 
surgical intervention related to melanoma. Of these, 83.3% 
(n = 15,055) received surgery after a melanoma diagnosis. 
The mean and median duration from the time of melanoma 
diagnosis to the last melanoma-related surgery prior to 
the start of IFN therapy was 126 ± 288 days and 28 (range 
0–2154) days, respectively. In total, 16.7% (n = 3020) of 
patients were diagnosed following surgery.
Among the 18,075 melanoma patients identified who 
had a confirmed claim of surgery related to melanoma, 
8.4% (n = 1525) were treated with IFN therapy and 91.6% 
(n = 16,550) were treated with non-IFN therapy within 60 days 
post-surgery. Of the patients with a surgery claim, 6.6% 
(n = 1194) had a confirmed claim for at least one of the stan-
dard of care chemotherapeutic agents for metastatic   melanoma. 
It should be noted that a subset of the CPT4 codes used to 
identify patients with a surgical intervention related to mela-
noma was labeled as “biopsy/lymph node removal”.  Although 
it could not be distinguished whether the code pertained to a 
surgical procedure conducted for diagnostic or intervention 
purposes, exploratory analyses were conducted excluding 
this subset of patients and the distribution with regard to IFN 
therapy was similar. Of 17,607 patients, 8.6% (n = 1506) were 
treated with IFN and 91.4% (n = 16,101) patients were treated 
with non-IFN therapy following surgery.
The characteristics and demographics for the melanoma 
patient population with a surgery claim and treated with 
adjuvant IFN or non-IFN therapy, along with results for 
statistical tests conducted between the two groups, are sum-
marized in Table 1.
Duration and frequency of iFN therapy
IFN therapy comprises two phases, ie, induction and mainte-
nance, for a total duration of one year. The induction phase 
consists of intravenous injections administered five times 
a week for 4 weeks, for a maximum of 20 doses. This is 
  followed by a maintenance phase of subcutaneous injections 
that are self-administered three times a week for 48 weeks, 
for a maximum of 144 doses.7
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
171
Adjuvant interferon for melanomaClinicoEconomics and Outcomes Research 2012:4
Among the 1525 melanoma patients who received IFN 
therapy within 60 days post-surgery (cohort C1), about 
half (n = 779, 51.1%) discontinued therapy within or after 
induction and half (n = 746, 48.9%) continued on to the 
maintenance phase (Table 2).
For the induction phase, patients received IFN 
therapy for approximately one month, with a mean and 
median duration of IFN therapy of 22 days and 25 days, 
  respectively, with broad ranges. Patients continued on IFN 
therapy into the maintenance phase, including induction, 
for approximately 3–5 months, with mean and median 
durations of 147 and 74 (range 30–707) days, respectively 
(Table 2).
Assessing the proportion of patients on IFN therapy for 
various durations, 51.1% were on therapy for one month, 
another 26.4% of patients continued to 3 months, and 17.8% 
from 6 months up to one year. The remaining 4.7% had at 
least one claim beyond one year, for reasons that cannot be 
obtained from an administrative claims database (Table 2). 
Ninety one percent of IFN patients were on therapy for some 
period of time during a one-year period.
Among melanoma patients who received IFN therapy 
within 60 days post-surgery, both the mean and median fre-
quency of doses during the induction phase for IFN therapy 
was 14. During the maintenance phase, the mean and median 
dose frequency was 40 and 23, respectively, with broad 
ranges (Table 2).
HCRU and costs of melanoma-related 
services
Health care resource utilization and average unit costs per 
service per melanoma patient are reported for cohort C1 
(n = 1525). Costs include those associated with the last sur-
gery prior to IFN therapy and those related to the subsequent 
treatment after surgery (Table 3).
The average total cost per patient for melanoma-related 
surgery was $2219 (n = 1525), with surgery cost being the 
most expensive component, averaging $1046 (n = 1525). The 
average cost per patient related to anesthesia, pathology, and 
hospital care was $858 (n = 639), $168 (n = 644), and $147 
(n = 746), respectively.
The average total cost per patient specifically related to 
adjuvant IFN therapy amounted to $1188, including drug 
cost (but not including any concomitant drug treatment 
costs). Any IFN regimen represents treatment of malignant 
melanoma patients at Stage IIB to III. On average, for a 
melanoma patient being treated with IFN, it cost a total of 
$374 (n = 1525) for services related to drug therapy. The cost 
per patient for complete blood count and thyroid-releasing 
hormone tests were $18 (n = 1231) and $34 (n = 134), 
(a) Melanoma patients (n = 178,817)
(b) Surgery patients (n = 18,075)
– Melanoma patients with confirmed claim for
surgical intervention related to melanoma
Melanoma diagnosis pre
surgery (n = 15,055)
Melanoma diagnosis post
surgery (n = 3,020)
(c2) Non-IFN patients (n = 16,550)
(c3) Non-IFN chemotherapy patients (n = 1194)
– Patients with confirmed claim for one or
 more standard of care chemotherapy*
(c1) IFN patients (n = 1,525)
– Patients with confirmed claim for IFN
  therapy within 60 days post-surgery
– Patients with confirmed claim for one or
   more other therapy
– Patients above the age of 18 with confirmed claim of melanoma diagnosis
   between Jan 1st, 2004 and Dec 31st, 2008
Figure 1 Identification of melanoma patients.
Note: *carboplatin, cisplatin, dacarbazine, paclitaxel, temozolomide.
Abbreviation: iFN, interferon alfa-2b.
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  respectively, while the cost associated with drug infusion 
was $255 (n = 1525). An office visit cost $67 (n = 1464). 
The average cost for drug only for each patient was $814 
(n = 1525).
In addition, the number of services and costs related to the 
drug-only portion of non-IFN standard of care   chemotherapy 
for metastatic melanoma (cohort C3, n = 1194) was also 
captured. These regimens represent treatment for Stage IV 
metastatic disease. Dacarbazine, temozolomide, cisplatin, 
carboplatin, and paclitaxel all have differing dosage schedules, 
as reflected in the varying number of claims among the drugs. 
Temozolomide, with the fewest claims, was the most expen-
sive standard of care agent ($2678; n = 39).   Corresponding 
costs ranged from $146 (n = 298) for dacarbazine and $202 
(n = 344) for cisplatin, to $715 (n = 530) and $886 (n = 578) 
for carboplatin and paclitaxel, respectively.
Table 1 Patient demographics and other baseline characteristics, 
by type of treatment
Demographic variable IFN  
therapy 
(n = 1525)
Non-IFN 
therapy 
(n = 16,550)
P value
Agea (years)*
  Mean ± SD 58 ± 12.0 57 ± 15.1 0.128
  Minimum-maximum 18–88 18–100
Genderb
  Male 898 (58.9%) 9004 (54.4%) 0.034
  Female 627 (41.1%) 7546 (45.6%)
Employmentb status*
  Active full time 455 (29.8%) 4759 (28.8%) ,0.0001
    Active part time or  
seasonal
10 (0.6%) 86 (0.5%)
  Early retiree 137 (9.0%) 1225 (7.4%)
  Medicare eligible retiree 165 (10.8%) 2990 (18.1%)
  Retiree (status unknown) 42 (2.8%) 782 (4.7%)
  COBRA continuee 30 (2.0%) 79 (0.5%)
  Long-term disability 7 (0.5%) 47 (0.3%)
    Surviving spouse/ 
dependent
6 (0.4%) 273 (1.6%)
  Other/unknown 671 (44.0%) 6309 (38.1%)
  Missing** 2 (0.1%) 0
Claim typeb
  Medicare supplemental 187 (12.0%) 1973 (11.9%) 0.700
  Commercial 1338 (88.0%) 14568 (88.0%)
  Missing** 0 9 (0.1%)
industryb
    Oil and gas extraction,  
mining
9 (0.6%) 130 (0.8%) 0.021
  Manufacturing, durable 244 (16.0%) 3230 (19.5%)
    Manufacturing,  
nondurable
72 (4.7%) 870 (5.3%)
    Transportation,  
communications, utilities
134 (8.8%) 1885 (11.4%)
  Retail trade 41 (2.7%) 281 (1.7%)
  Finance, insurance, real 69 (4.5%) 885 (5.4%)
  Services 89 (5.8%) 878 (5.2%)
  Missing** 867 (56.9%) 8391 (50.7%)
Notes: at-test used to compare means in the iFN and non-iFN therapy groups; 
bChi-square tests used to compare proportions in the iFN and non-iFN therapy 
groups; *age and employment status were calculated based on time of the surgery 
claim; **missing data was included to calculate the Chi-square tests.
Abbreviations:  COBRA,  Consolidated  Omnibus  Budget  Reconciliation  Act;   
iFN, interferon alfa-2b; n, number of patients; SD, standard deviation.
Table 2 iFN therapy duration and frequency from claims data of 
melanoma patients post-surgery
Induction* Maintenance† Total
Patients (%) 779 (51.1%) 746 (48.9%) 1525
Duration (days)
  Mean ± SD 22 ± 8.3 147 ± 164.3 79 ± 109.6
  Median (range) 25 (1–28) 74 (30–707) 29 (1–707)
Proportion of patients on iFN therapy for various durations (%)
 # 29 days 51.1
  30–90 days 26.4
  91–180 days 7.6
  181–365 days 10.2
 . 365 days 4.7
Number of iFN doses (claims)
  Mean ± SD 14 ± 6.6 40 ± 38.9 28 ± 30.4
  Median (range) 14 (1–21**) 23 (2–239***) 20 (1–239)
Notes: *induction phase, doses 5 times per week for 4 weeks for a maximum of 
20 doses; †maintenance phase, doses 3 times a week for 48 weeks for a maximum 
of 144 doses; outliers **one extra dose given in the one-month period; ***second 
set of doses administered exceptionally to one patient following a break after the 
first set of doses.
Abbreviations: iFN, interferon alfa-2b; SD, standard deviation.
Table  3  Health  care  resource  utilization  and  2009  costs  for 
treating adjuvant melanoma
Service n N Average unit cost per service   
per patient in USD (±SD)
Melanoma-related surgery among patients on iFN therapy  
post-surgery (n = 1525)
  Surgery 1525 1525 1046 (879.88)
  Anesthesia 639 639 858 (472.96)
  Pathology 644 732 168 (144.58)
  Hospital care 746 746 147 (56.59)
  Total surgery cost 2219
Adjuvant iFN therapy post-surgery (n = 1525)
  Office visit 1464 14,637 67 (24.21)
  CBC panel 1231 8341 18 (35.39)
  TRH stimulation 134 331 34 (41.44)
    infusion  
administration*
1525 16,219 255 (143.34)
  Total IFN services cost 374
  iFN (drug only) 1525 41,372 814 (525.15)
Chemotherapy post-surgery (n = 1194)
  Dacarbazine 298 2218 146 (111.23)
  Temozolomide 39 181 2678 (1893.96)
  Cisplatin 344 2710 202 (177.63)
  Carboplatin 530 2827 715 (1077.94)
  Paclitaxel 578 3825 886 (792.76)
Note:  *CPT4  code  used  for  infusion  administration  (96413)  became  effective 
January 1, 2006.
Abbreviations: n, number of patients; N, number of services (claims); SD, standard 
deviation; iFN, interferon alfa-2b; CBC, complete blood count; TRH, thyroid releasing 
hormone; USD, United States dollars.
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Discussion
Using real-world claims data, this study identified popula-
tions that had undergone surgery for malignant melanoma and 
subsequently received IFN therapy or non-IFN standard of 
care chemotherapy. According to the indications for IFN and 
non-IFN chemotherapies, these treatments describe adjuvant 
therapy for patients with Stage IIB to III malignant melanoma 
and with Stage IV metastatic melanoma, respectively.
For the population who received IFN therapy, the dura-
tion of total therapy (induction and maintenance combined) 
was on average 3–5 months. However, approximately 50% 
of patients discontinued therapy within or after induction, for 
reasons that cannot be obtained from an administrative claims 
database study like this. The median number of total doses 
for IFN therapy was 20, corresponding to the total number 
of doses for the induction phase according to the Intron A 
product label.7 This indicates that patients seem to complete 
the induction phase of therapy which requires infusion, and 
then discontinue, not moving onto the self-administered 
maintenance phase of therapy. Further study to investigate 
reasons for discontinuation may be warranted. In addition, 
91% of patients were on IFN therapy for some period of 
time during a one-year period. There is no known published 
source regarding the duration of IFN therapy as observed in 
the pivotal clinical trials, but the median relapse-free survival 
for IFN observed was 1.72 years compared with 0.98 years 
for observation.14
To optimize treatment outcomes, it is important to adhere 
to recommended therapy regimens. A study by Agarwala et al 
indicated that 4 weeks of therapy with IFN, equivalent to the 
induction phase alone, did not show improvement in relapse-
free survival (6.8 years compared with 7.3 years for obser-
vation) in patients with intermediate (81% of IFN-treated 
population) or high-risk (19% of IFN-treated population) 
melanoma.15 This is in contrast with the increase observed in 
the pivotal trial, noted earlier.14 However, there is no publicly 
available scientific source documenting the duration of IFN 
therapy from either of these trials. The study by Agarwala 
et al suggests that longer duration of IFN treatment may be 
important.15 Adherence to the recommended dosage and 
administration of IFN in the high-risk population should 
be an important part of patient education to maximize the 
benefits of therapy.
Possible factors contributing toward discontinuation of 
IFN therapy may be inconvenience of infusion administration 
and frequency of therapy during the induction phase, as well 
as toxicity related to therapy.16 Newer therapies are available 
for Stage III disease, such as a PEGylated version of IFN 
(Sylatron™) which, in contrast with non-PEGylated inter-
ferons, allows for less frequent dosing because of delayed 
renal clearance. In addition, dosing modification guidelines 
exist for PEGylated IFN which are intended to manage any 
associated toxicity and allow patients to stay on therapy for 
as long possible. The proposed course of treatment with 
PEGylated IFN for melanoma involves an induction phase 
of one dose per week subcutaneously for 8 weeks, followed 
by a maintenance phase of half that dose once per week 
subcutaneously for up to 5 years.17 This dosing form allows 
for self-administration, thereby eliminating costs associated 
with infusion, such as for IFN.
Two of the largest cost components of the annual direct 
cost of diagnosing and treating melanoma in the US are 
reported from a modeling study to be adjuvant IFN therapies 
(27%, $151 million) and terminal care (35%, $197 million).18 
This was confirmed by a US economic model that found the 
most expensive elements of medical care among patients with 
melanoma to be adjuvant IFN therapy at about $76,000 per 
patient, and palliative care at $14,500 per patient.19 This is 
supported by another US study which showed that hospital 
services were the main contributor to the high cost of malig-
nant melanoma on a per patient basis among subjects aged 
65 years and older who had a malignant melanoma diagnosis 
of at least stage IIB or higher.9 Differences in methodology 
among studies preclude direct comparison of cost results.
For the current study, cost refers to the amount paid to 
providers associated with the health service; because these 
are reimbursement rates, actual costs could be lower than 
what is reported. Looking at the study results, average unit 
costs for surgery itself accounted for most of a patient’s total 
melanoma-related surgery costs at $1046 out of $2219. The 
average unit cost for IFN drug therapy only was $814, while 
average unit costs for other chemotherapy drugs ranged from 
$146 to $2678. However, these values should be taken in 
context with the patient populations they treat, IFN is used 
for patients with Stage IIB to III disease, which are a larger 
segment of the melanoma patient population compared with 
patients at Stage IV . In addition, patients at the earlier stages 
have a better chance for survival and continuing on   treatment. 
Further, the number of single-agent or combination regimen 
chemotherapy cycles completed also contributes toward 
the cost. Therefore, comparisons cannot be made in this 
regard.
There were limitations in conducting this retrospective 
database study. The stage of disease could not be confirmed 
due to the absence of staging information in the database; it 
was assumed that receipt of IFN therapy following surgery 
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defined patients with at least regional disease. Secondly, the 
proportion of patients that were part of a clinical trial was 
unknown and may influence claims generated if services 
were reimbursed by other sources, thus causing potential 
for underestimation of some costs. Also, inclusion of only 
fee-for-service patients may have introduced selection bias, 
though the majority of patients were enrolled in this plan type. 
Lastly, patient adherence could not be assessed due to lack of 
information on aspects such as disease management and how 
IFN was administered during the treatment phases.
Conclusion
This study observes that there is an unmet treatment need 
because melanoma patients on IFN therapy post-surgery 
enrolled in this claims database did not complete the recom-
mended one-year course of treatment, and half of patients 
discontinued therapy within or after the induction phase; this 
may compromise the full therapeutic benefits of IFN therapy. 
Further, costs associated with adjuvant IFN therapy in post-
surgical treatment of disease are likely acceptable.
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Supplementary table
Table S1 CPT4 and J codes used in claims data analysis of melanoma patients
CPT4 codes for surgical intervention*
38500/38510/38520/38525/38530 Biopsy/removal, lymph nodes
38505 Needle biopsy, lymph nodes
38562 Removal, pelvic lymph nodes
38564 Removal, abdomen lymph nodes
38570 Laparoscopy, lymph node biopsy
38571/38572 Laparoscopy, lymphadenectomy
38700/38720/38724 Removal of lymph nodes, neck
38740/38745 Remove armpit lymph nodes
38746 Remove thoracic lymph nodes
38747 Remove abdominal lymph nodes
38760/38765 Remove groin lymph nodes
38770 Remove pelvis lymph nodes
38780 Remove abdomen lymph nodes
CPT4 codes for HCRU associated with surgery*
00100–01999 All anesthetic codes
88302/88304/88305/88307/88309 Tissue examination by pathologist
80500/80502 Laboratory pathology consultation
88399 Surgical pathology procedure
89240 Pathology laboratory procedure
99218/99219/99220 Observation care
99221/99222/99223 initial hospital care
99234/99235/99236 Observation/hospitalization same date
99238/99239 Hospital discharge day
99251/99252/99253/99254/99255 inpatient consultation
CPT4 codes For HCRU associated with IFN therapy*
96413 Chemotherapy administration, intravenous infusion technique; up to one 
hour, single or initial substance/drug
99201/99202/99203/99204/99205 Office/outpatient visit, new
99211/99212/99213/99214/99215 Office/outpatient visit
CPT4 codes for blood laboratory work associated with IFN therapy*
85025 Complete CBC with auto differential WBC
80438/80439/80440 TRH stimulation panel
J codes for drug therapy associated with a melanoma diagnosis**
J9214 injection, interferon, alfa-2b, recombinant, one million units (iFN) A
J9130 Dacarbazine, 100 mg
J9140 Dacarbazine, 200 mg
J8700 Temozolomide, oral, 5 mg
J9060 Cisplatin, powder or solution, per 10 mg
J9062 Cisplatin, 50 mg
J9045 injection, carboplatin, 50 mg
J9265 injection, paclitaxel, 30 mg
Notes: *American Medical Association, 2009; **Centers for Medicare and Medicaid Services, 2009.
Abbreviations: CPT, Current Procedural Terminology; HCRU, health care resource use; iFN, interferon alfa-2b; WBC, white blood cell count; CBC, complete blood 
count.
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